ClinicalTrials.gg
CompletedNCT03665597Updated Feb 10, 2025Results posted

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

A Phase 1 interventional study of Pembrolizumab Dose C and Pembrolizumab Dose A in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 42 studies in Melanoma by Merck & Co., Inc — 1 open to participants now, 6 under way, 3 of them phase 3. Melanoma · Merck & Co., Inc.

Enrollment
19th of 39
138 · median 131
Started
2018
with 2 others
Phase 1
13 of 42
none open now
Registered
28th of 42
by date

Among the 42 studies in Melanoma by Merck & Co., Inc, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2018, is one of 13 in phase 1, and was the 28th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 42 studies in Melanoma by Merck & Co., Inc is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Melanoma by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the pharmacokinetic (PK) profile of pembrolizumab (MK-3475) following single subcutaneous (SC) injection of pembrolizumab Dose A versus pembrolizumab Dose C in adults with advanced melanoma. Additionally, the safety and tolerability of pembrolizumab SC injections will be assessed. And, finally, the efficacy of pembrolizumab intravenous (IV) infusion administration will be assessed.

Read the detailed description

This study consists of two cohorts. Participants in Cohort A are randomized to one of six treatment sequences which will include 2 cycles of pembrolizumab administered via subcutaneous injection and 1 cycle of intravenous (IV) infusion, followed by up to 32 cycles (up to \~2 years) of pembrolizumab administered via IV infusion (each cycle is 21 days). Participants in Cohort B will receive pembrolizumab via IV infusion on Day 1 of each 21-day cycle for up to 18 cycles, up to \~ 2 years. Each cycle is 42 days.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Programmed Cell Death 1
  • PD1
  • PD-1
  • Programmed Cell Death-Ligand 1
  • PDL1
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed diagnosis of advanced melanoma.
  • Has unresectable Stage III or Stage IV melanoma, as per American Joint Committee on Cancer (AJCC) staging system not amenable to local therapy.
  • Has been untreated for advanced or disease except as follows:
  • a. BRAF V600 mutant melanoma may have received standard of care targeted therapy (e.g. BRAF/ mitogen-activated protein kinase kinase enzyme [MEK] inhibitor, alone or in combination) and be eligible for this study.
  • b. Prior adjuvant (post-surgery) or (pre-surgery) melanoma therapy is permitted if it was completed ≥4 weeks before randomization and all related AEs have either returned to baseline or stabilized (resolution of toxic effect[s] of the most recent prior therapy to Grade 1 or less [except alopecia]).
  • Female participants must agree to use during the treatment period and for ≥120 days after the last dose of study treatment.
  • Has per 1.1 as assessed by BICR. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Has an (ECOG) performance status of 0 to 1.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has received prior systemic treatment for unresectable or melanoma (exceptions as noted above in the Inclusion Criteria).
  • Has received prior therapy with an anti-programmed cell death 1 (), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. OX-40 and CD137) or any other antibody or drug specifically targeting checkpoint pathways other than anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) which is permitted in the setting.
  • Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require , and not have had radiation pneumonitis.
  • Has received a within 30 days prior to the first dose of study treatment.
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study treatment.
  • Has a known additional that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
  • Has known active central nervous system metastases and/or carcinomatous meningitis.
  • Has severe (≥Grade 3) to pembrolizumab and/or any of its .
  • Has ocular melanoma.
  • Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
  • Has an active infection requiring systemic therapy.
  • Has a known history of (HIV) infection.
  • Has a known history of or known active virus infection.
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.
  • Has had an allogenic tissue/solid organ transplant.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Cohort A Pembrolizumab Treatment Sequence 1

    Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 165 mg/mL subcutaneously (SC); Cycle 2 Day 1: pembrolizumab 200 mg intravenously (IV); Cycle 3 Day 1: pembrolizumab 130 mg/mL SC; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.

    Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B

  • Experimental
    Cohort A Pembrolizumab Treatment Sequence 2

    Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 165 mg/mL SC; Cycle 2 Day 1: pembrolizumab 130 mg/mL SC; Cycle 3 Day 1: pembrolizumab 200 mg IV; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.

    Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B

  • Experimental
    Cohort A Pembrolizumab Treatment Sequence 3

    Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 130 mg/mL SC; Cycle 2 Day 1: pembrolizumab 165 mg/mL SC; Cycle 3 Day 1: pembrolizumab 200 mg IV; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.

    Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B

  • Experimental
    Cohort A Pembrolizumab Treatment Sequence 4

    Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 200 mg SC; Cycle 2 Day 1: pembrolizumab 200 mg IV; Cycle 3 Day 1: pembrolizumab 130 mg/mL SC; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab Dose 200 mg IV.

    Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B

  • Experimental
    Cohort A Pembrolizumab Treatment Sequence 5

    Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 200 mg IV; Cycle 2 Day 1: pembrolizumab 130 mg/mL SC; Cycle 3 Day 1: pembrolizumab 165 mg/mL SC: Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.

    Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B

  • Experimental
    Cohort A Pembrolizumab Treatment Sequence 6

    Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 200 mg IV; Cycle 2 Day 1: pembrolizumab 165 mg/mL SC; Cycle 3 Day 1: pembrolizumab 130 mg/mL SC; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.

    Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B

  • Experimental
    Cohort B Pembrolizumab 400 mg IV

    Participants receive a single dose of pembrolizumab 400 mg IV on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for up to 18 cycles (up to approximately 2 years).

    Biological: Pembrolizumab Dose D

Interventions

  • BiologicalPembrolizumab Dose C

    165 mg/mL administered to a final dose of 285 mg via subcutaneous injection

    Also known as: KEYTRUDA®, MK-3475

  • BiologicalPembrolizumab Dose A

    130 mg/mL administered to a final dose of 285 mg via subcutaneous injection

    Also known as: KEYTRUDA®, MK-3475

  • BiologicalPembrolizumab Dose B

    200 mg administered via intravenous infusion

    Also known as: KEYTRUDA®, MK-3475

  • BiologicalPembrolizumab Dose D

    400 mg administered via intravenous infusion

    Also known as: KEYTRUDA®, MK-3475

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve (AUC) of Pembrolizumab - Cohort A

    AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points and a pharmacokinetic (PK) model based on historical intravenous pembrolizumab PK data were used for the determination of the AUC of pembrolizumab. Geometric least-square mean (GM) and 95% confidence intervals were derived from mixed-effects model performed on natural log-transformed values. Data were reported by treatment received.

    Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.

  2. Maximum Plasma Concentration (Cmax) of Pembrolizumab - Cohort A

    Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points and a PK model based on historical intravenous pembrolizumab PK data were used for the determination of the AUC of pembrolizumab. GM and 95% confidence intervals were derived from mixed-effects model performed on natural log-transformed values. Data were reported by treatment received.

    Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.

  3. Bioavailability (F) of Pembrolizumab - Cohort A

    Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the F of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.

    Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.

  4. Absorption Rate Constant (Ka) of Pembrolizumab - Cohort A

    Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the Ka of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported. Participants in Cohort B weren't analyzed, per protocol.

    Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.

  5. Time of Maximum Plasma Concentration (Tmax) of Pembrolizumab - Cohort A

    Blood samples were collected at designated time points for the determination of the Tmax of pembrolizumab.

    Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.

  6. Clearance (CL) of Pembrolizumab - Cohort A

    Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the CL of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.

    Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.

  7. Central Volume of Distribution (Vc) of Pembrolizumab - Cohort A

    Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the Vc of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.

    Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.

  8. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Cohort B

    ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). Responses were based upon blinded independent central review (BICR) per RECIST 1.1. ORR was reported for participants in Cohort B.

    Time frame: Up to approximately 54 months

Secondary outcomes

  1. Number of Participants Positive for Pembrolizumab Anti-Drug Antibody (ADA) Formation - Cohort A

    Blood samples were collected at designated time points for the determination of the presence or absence of pembrolizumab anti-drug antibodies. The number of participants who develop anti-pembrolizumab antibodies were assessed in Cycles 1 through Cycle 4. Per ADA immunogenicity analysis report, data from participants in Cohort A were reported combined across treatment cycles 1-4.

    Time frame: Cycles 1-4 Day 1: Predose. Each cycle is 21 days. (Up to approximately 64 days)

  2. Number of Participants Who Experienced One or More Adverse Event (AEs) - Cohort A

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced one or more AEs in Cohort A was reported. Per protocol, data were reported by treatment received and AEs from Cycles 4-35 were reported separately.

    Time frame: Up to approximately 27 months

  3. Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort A

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued due to an AE in Cohort A were reported. Per protocol, data were reported by treatment received and data from Cycles 4-35 were reported separately.

    Time frame: Up to approximately 23 months

  4. Number of Participants With One or More Injection Site Signs and Symptoms After Subcutaneous Pembrolizumab Injection in Cycles 1-3 - Cohort A

    Participants completed the Injection Site Signs and Symptoms Questionnaire, within 60 minutes after each pembrolizumab SC injection during Cycles 1-3. Participants rated any pain, itching, swelling and redness they experienced at the pembrolizumab SC injection site from "None" to "Severe". The number of participants who experienced an injection site sign or symptom was reported.

    Time frame: Cycles 1-3 Day 1: Up to 60 minutes postdose. Each cycle is 21 days. (Up to approximately 43 days)

  5. Duration of Response (DOR) Per RECIST 1.1 - Cohort B

    For participants who demonstrated a CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR was calculated for RECIST 1.1 based on BICR. DOR for Cohort B was reported.

    Time frame: Up to approximately 54 months

  6. Progression-free Survival (PFS) Per to RECIST v1.1 Modified to Follow a Maximum of 10 Target Lesions and a Maximum of 5 Target Lesions Per Organ - Cohort B

    PFS was defined as the time from the first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Although RECIST 1.1 was modified to allow for a maximum of 10 target lesions in total and 5 per organ. Per protocol, PFS as assessed by BICR for participants in Cohort B was reported.

    Time frame: Up to approximately 54 months

  7. Overall Survival (OS) - Cohort B

    OS was defined as the time from the first dose of study treatment to death due to any cause. Per protocol, OS for participants in Cohort B was reported.

    Time frame: Up to approximately 54 months

  8. Early Cycle AUC of Pembrolizumab - Cohort B

    AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points for the determination of the pembrolizumab AUC in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. A cycle was 42 days.

    Time frame: Cycle 1: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 2: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)

  9. Steady State AUC of Pembrolizumab - Cohort B

    AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points for the determination of the pembrolizumab AUC in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last samples (trough concentration) of Cycle 4. Each cycle was 42 days.

    Time frame: Cycle 4: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 5: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)

  10. Early Cycle Cmax of Pembrolizumab - Cohort B

    Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmax in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. Each cycle was 42 days.

    Time frame: Cycle 1: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 2: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)

  11. Steady State Cmax of Pembrolizumab - Cohort B

    Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmax in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last sample (trough concentration) of Cycle 4. Each cycle was 42 days.

    Time frame: Cycle 4: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 5: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)

  12. Early Cycle Minimum Plasma Concentration (Cmin) of Pembrolizumab - Cohort B

    Cmin was defined as the minimum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmin in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. Each cycle was 42 days.

    Time frame: Cycle 1: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 2: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)

  13. Steady State Cmin of Pembrolizumab - Cohort B

    Cmin was defined as the minimum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmin in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last sample (trough concentration) of Cycle 4. Each cycle was 42 days.

    Time frame: Cycle 4: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 5: Predose. Each Cycle was 42 days. (Up to approximately 6 weeks)

  14. Number of Participants Who Experienced One or More AEs - Cohort B

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced one or more AEs in Cohort B was reported.

    Time frame: Up to approximately 54 months

  15. Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort B

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued due to an AE in Cohort B were reported.

    Time frame: Up to approximately 26 months

07

Results

Posted Feb 10, 2025

Participant flow

Period 1
Participant flow — Period 1
MilestoneCohort A Pembrolizumab Treatment Sequence 1Cohort A Pembrolizumab Treatment Sequence 2Cohort A Pembrolizumab Treatment Sequence 3Cohort A Pembrolizumab Treatment Sequence 4Cohort A Pembrolizumab Treatment Sequence 5Cohort A Pembrolizumab Treatment Sequence 6Cohort B Pembrolizumab 400 mg IV
Started766657101
Treated766557101
Completed66645751
Not completed10020050
Withdrew: Adverse event1001000
Withdrew: Screen failure0001000
Withdrew: Death00000045
Withdrew: Withdrawal by subject0000005
Period 2
Participant flow — Period 2
MilestoneCohort A Pembrolizumab Treatment Sequence 1Cohort A Pembrolizumab Treatment Sequence 2Cohort A Pembrolizumab Treatment Sequence 3Cohort A Pembrolizumab Treatment Sequence 4Cohort A Pembrolizumab Treatment Sequence 5Cohort A Pembrolizumab Treatment Sequence 6Cohort B Pembrolizumab 400 mg IV
Started6664570
Treated6664470
Completed6664560
Not completed0000010
Withdrew: Adverse event0000010
Period 3
Participant flow — Period 3
MilestoneCohort A Pembrolizumab Treatment Sequence 1Cohort A Pembrolizumab Treatment Sequence 2Cohort A Pembrolizumab Treatment Sequence 3Cohort A Pembrolizumab Treatment Sequence 4Cohort A Pembrolizumab Treatment Sequence 5Cohort A Pembrolizumab Treatment Sequence 6Cohort B Pembrolizumab 400 mg IV
Started6664560
Treated6664460
Completed6564460
Not completed0100100
Withdrew: Adverse event0100000
Withdrew: Death0000100
Period 4
Participant flow — Period 4
MilestoneCohort A Pembrolizumab Treatment Sequence 1Cohort A Pembrolizumab Treatment Sequence 2Cohort A Pembrolizumab Treatment Sequence 3Cohort A Pembrolizumab Treatment Sequence 4Cohort A Pembrolizumab Treatment Sequence 5Cohort A Pembrolizumab Treatment Sequence 6Cohort B Pembrolizumab 400 mg IV
Started6564460
Treated6564360
Completed3122360
Not completed3442100
Withdrew: Adverse event2222100
Withdrew: Death0020000
Withdrew: Physician decision1200000

Outcome measures

PrimaryArea Under the Concentration-Time Curve (AUC) of Pembrolizumab - Cohort A

AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points and a pharmacokinetic (PK) model based on historical intravenous pembrolizumab PK data were used for the determination of the AUC of pembrolizumab. Geometric least-square mean (GM) and 95% confidence intervals were derived from mixed-effects model performed on natural log-transformed values. Data were reported by treatment received.

Time frame:
Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Reported as:
Geometric least squares mean · mg*day/L
Area Under the Concentration-Time Curve (AUC) of Pembrolizumab - Cohort A
mg*day/LCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IV
Area Under the Concentration-Time Curve (AUC) of Pembrolizumab - Cohort A507 (440 to 585)480 (418 to 551)695 (631 to 766)
Statistical analysis
  • Cohort A Pembrolizumab 130 mg/mL SC vs Cohort A Pembrolizumab 200 mg IV · Gmr: 0.73 · 90% CI 0.68 to 0.78
  • Cohort A Pembrolizumab 165 mg/mL SC vs Cohort A Pembrolizumab 200 mg IV · Gmr: 0.69 · 90% CI 0.64 to 0.74
PrimaryMaximum Plasma Concentration (Cmax) of Pembrolizumab - Cohort A

Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points and a PK model based on historical intravenous pembrolizumab PK data were used for the determination of the AUC of pembrolizumab. GM and 95% confidence intervals were derived from mixed-effects model performed on natural log-transformed values. Data were reported by treatment received.

Time frame:
Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Reported as:
Geometric least squares mean · mg/L
Maximum Plasma Concentration (Cmax) of Pembrolizumab - Cohort A
mg/LCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IV
Maximum Plasma Concentration (Cmax) of Pembrolizumab - Cohort A28.6 (24.7 to 33.1)26.8 (23.2 to 30.9)71.3 (65.6 to 77.5)
Statistical analysis
  • Cohort A Pembrolizumab 130 mg/mL SC vs Cohort A Pembrolizumab 200 mg IV · Geometric least-square mean ratio: 0.40 · 90% CI 0.36 to 0.44
  • Cohort A Pembrolizumab 165 mg/mL SC vs Cohort A Pembrolizumab 200 mg IV · Geometric least-square mean ratio: 0.38 · 90% CI 0.34 to 0.41
PrimaryBioavailability (F) of Pembrolizumab - Cohort A

Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the F of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.

Time frame:
Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Reported as:
Mean · Percent
Bioavailability (F) of Pembrolizumab - Cohort A
PercentCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IVCombined Cohort A
Bioavailability (F) of Pembrolizumab - Cohort A———66 (58 to 74)
PrimaryAbsorption Rate Constant (Ka) of Pembrolizumab - Cohort A

Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the Ka of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported. Participants in Cohort B weren't analyzed, per protocol.

Time frame:
Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Reported as:
Mean · 1/day
Absorption Rate Constant (Ka) of Pembrolizumab - Cohort A
1/dayCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IVCombined Cohort A
Absorption Rate Constant (Ka) of Pembrolizumab - Cohort A———0.191 ± 13.1
PrimaryTime of Maximum Plasma Concentration (Tmax) of Pembrolizumab - Cohort A

Blood samples were collected at designated time points for the determination of the Tmax of pembrolizumab.

Time frame:
Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Reported as:
Median · Days
Time of Maximum Plasma Concentration (Tmax) of Pembrolizumab - Cohort A
DaysCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3)
Time of Maximum Plasma Concentration (Tmax) of Pembrolizumab - Cohort A6.55 (3.70 to 21.00)8.35 (3.00 to 21.00)0.02 (0.02 to 0.02)
PrimaryClearance (CL) of Pembrolizumab - Cohort A

Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the CL of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.

Time frame:
Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Reported as:
Mean · Liters/day
Clearance (CL) of Pembrolizumab - Cohort A
Liters/dayCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IVCombined Cohort A
Clearance (CL) of Pembrolizumab - Cohort A———0.25 ± 6.28
PrimaryCentral Volume of Distribution (Vc) of Pembrolizumab - Cohort A

Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the Vc of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.

Time frame:
Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Reported as:
Mean · Liters
Central Volume of Distribution (Vc) of Pembrolizumab - Cohort A
LitersCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IVCombined Cohort A
Central Volume of Distribution (Vc) of Pembrolizumab - Cohort A———3.39 ± 5.68
PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Cohort B

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). Responses were based upon blinded independent central review (BICR) per RECIST 1.1. ORR was reported for participants in Cohort B.

Time frame:
Up to approximately 54 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Cohort B
Percentage of ParticipantsCohort B Pembrolizumab 400 mg IV
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Cohort B53.5 (43.3 to 63.5)
SecondaryNumber of Participants Positive for Pembrolizumab Anti-Drug Antibody (ADA) Formation - Cohort A

Blood samples were collected at designated time points for the determination of the presence or absence of pembrolizumab anti-drug antibodies. The number of participants who develop anti-pembrolizumab antibodies were assessed in Cycles 1 through Cycle 4. Per ADA immunogenicity analysis report, data from participants in Cohort A were reported combined across treatment cycles 1-4.

Time frame:
Cycles 1-4 Day 1: Predose. Each cycle is 21 days. (Up to approximately 64 days)
Reported as:
Count of participants · Participants
Number of Participants Positive for Pembrolizumab Anti-Drug Antibody (ADA) Formation - Cohort A
ParticipantsCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IVCombined Cohort A
Number of Participants Positive for Pembrolizumab Anti-Drug Antibody (ADA) Formation - Cohort A———0
SecondaryNumber of Participants Who Experienced One or More Adverse Event (AEs) - Cohort A

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced one or more AEs in Cohort A was reported. Per protocol, data were reported by treatment received and AEs from Cycles 4-35 were reported separately.

Time frame:
Up to approximately 27 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Adverse Event (AEs) - Cohort A
ParticipantsCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3)Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35)
Number of Participants Who Experienced One or More Adverse Event (AEs) - Cohort A18181429
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE - Cohort A

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued due to an AE in Cohort A were reported. Per protocol, data were reported by treatment received and data from Cycles 4-35 were reported separately.

Time frame:
Up to approximately 23 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort A
ParticipantsCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3)Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35)
Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort A1015
SecondaryNumber of Participants With One or More Injection Site Signs and Symptoms After Subcutaneous Pembrolizumab Injection in Cycles 1-3 - Cohort A

Participants completed the Injection Site Signs and Symptoms Questionnaire, within 60 minutes after each pembrolizumab SC injection during Cycles 1-3. Participants rated any pain, itching, swelling and redness they experienced at the pembrolizumab SC injection site from "None" to "Severe". The number of participants who experienced an injection site sign or symptom was reported.

Time frame:
Cycles 1-3 Day 1: Up to 60 minutes postdose. Each cycle is 21 days. (Up to approximately 43 days)
Reported as:
Count of participants · Participants
Number of Participants With One or More Injection Site Signs and Symptoms After Subcutaneous Pembrolizumab Injection in Cycles 1-3 - Cohort A
ParticipantsCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3)
Number of Participants With One or More Injection Site Signs and Symptoms After Subcutaneous Pembrolizumab Injection in Cycles 1-3 - Cohort A32—
SecondaryDuration of Response (DOR) Per RECIST 1.1 - Cohort B

For participants who demonstrated a CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR was calculated for RECIST 1.1 based on BICR. DOR for Cohort B was reported.

Time frame:
Up to approximately 54 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 - Cohort B
MonthsCohort B Pembrolizumab 400 mg IV
Duration of Response (DOR) Per RECIST 1.1 - Cohort BNA (NA to NA)
SecondaryProgression-free Survival (PFS) Per to RECIST v1.1 Modified to Follow a Maximum of 10 Target Lesions and a Maximum of 5 Target Lesions Per Organ - Cohort B

PFS was defined as the time from the first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Although RECIST 1.1 was modified to allow for a maximum of 10 target lesions in total and 5 per organ. Per protocol, PFS as assessed by BICR for participants in Cohort B was reported.

Time frame:
Up to approximately 54 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per to RECIST v1.1 Modified to Follow a Maximum of 10 Target Lesions and a Maximum of 5 Target Lesions Per Organ - Cohort B
MonthsCohort B Pembrolizumab 400 mg IV
Progression-free Survival (PFS) Per to RECIST v1.1 Modified to Follow a Maximum of 10 Target Lesions and a Maximum of 5 Target Lesions Per Organ - Cohort B13.8 (5.3 to 41.4)
SecondaryOverall Survival (OS) - Cohort B

OS was defined as the time from the first dose of study treatment to death due to any cause. Per protocol, OS for participants in Cohort B was reported.

Time frame:
Up to approximately 54 months
Reported as:
Median · Months
Overall Survival (OS) - Cohort B
MonthsCohort B Pembrolizumab 400 mg IV
Overall Survival (OS) - Cohort BNA (27.1 to NA)
SecondaryEarly Cycle AUC of Pembrolizumab - Cohort B

AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points for the determination of the pembrolizumab AUC in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. A cycle was 42 days.

Time frame:
Cycle 1: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 2: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Reported as:
Median · μg/ml
Early Cycle AUC of Pembrolizumab - Cohort B
μg/mlCohort B Pembrolizumab 400 mg IV
Early Cycle AUC of Pembrolizumab - Cohort BNA (NA to NA)
SecondarySteady State AUC of Pembrolizumab - Cohort B

AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points for the determination of the pembrolizumab AUC in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last samples (trough concentration) of Cycle 4. Each cycle was 42 days.

Time frame:
Cycle 4: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 5: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Reported as:
Median · μg/ml
Steady State AUC of Pembrolizumab - Cohort B
μg/mlCohort B Pembrolizumab 400 mg IV
Steady State AUC of Pembrolizumab - Cohort BNA (NA to NA)
SecondaryEarly Cycle Cmax of Pembrolizumab - Cohort B

Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmax in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. Each cycle was 42 days.

Time frame:
Cycle 1: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 2: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Reported as:
Median · μg/ml
Early Cycle Cmax of Pembrolizumab - Cohort B
μg/mlCohort B Pembrolizumab 400 mg IV
Early Cycle Cmax of Pembrolizumab - Cohort B127.0 (121.3 to 132.7)
SecondarySteady State Cmax of Pembrolizumab - Cohort B

Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmax in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last sample (trough concentration) of Cycle 4. Each cycle was 42 days.

Time frame:
Cycle 4: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 5: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Reported as:
Median · μg/ml
Steady State Cmax of Pembrolizumab - Cohort B
μg/mlCohort B Pembrolizumab 400 mg IV
Steady State Cmax of Pembrolizumab - Cohort B150.0 (141.9 to 158.3)
SecondaryEarly Cycle Minimum Plasma Concentration (Cmin) of Pembrolizumab - Cohort B

Cmin was defined as the minimum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmin in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. Each cycle was 42 days.

Time frame:
Cycle 1: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 2: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Reported as:
Median · μg/ml
Early Cycle Minimum Plasma Concentration (Cmin) of Pembrolizumab - Cohort B
μg/mlCohort B Pembrolizumab 400 mg IV
Early Cycle Minimum Plasma Concentration (Cmin) of Pembrolizumab - Cohort B15.1 (13.5 to 16.9)
SecondarySteady State Cmin of Pembrolizumab - Cohort B

Cmin was defined as the minimum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmin in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last sample (trough concentration) of Cycle 4. Each cycle was 42 days.

Time frame:
Cycle 4: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 5: Predose. Each Cycle was 42 days. (Up to approximately 6 weeks)
Reported as:
Median · μg/ml
Steady State Cmin of Pembrolizumab - Cohort B
μg/mlCohort B Pembrolizumab 400 mg IV
Steady State Cmin of Pembrolizumab - Cohort B24.0 (20.6 to 27.9)
SecondaryNumber of Participants Who Experienced One or More AEs - Cohort B

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced one or more AEs in Cohort B was reported.

Time frame:
Up to approximately 54 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More AEs - Cohort B
ParticipantsCohort B Pembrolizumab 400 mg IV
Number of Participants Who Experienced One or More AEs - Cohort B101
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE - Cohort B

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued due to an AE in Cohort B were reported.

Time frame:
Up to approximately 26 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort B
ParticipantsCohort B Pembrolizumab 400 mg IV
Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort B8

Adverse events

Collected over Up to approximately 54 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A Pembrolizumab 130 mg/mL SC1/34 (2.9%)1/33 (3%)15/33 (45.5%)
Cohort A Pembrolizumab 165 mg/mL SC3/35 (8.6%)2/34 (5.9%)15/34 (44.1%)
Cohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3)1/35 (2.9%)2/34 (5.9%)8/34 (23.5%)
Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35)4/31 (12.9%)9/30 (30%)27/30 (90%)
Cohort B Pembrolizumab 400 mg IV45/101 (44.6%)31/101 (30.7%)93/101 (92.1%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3)Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35)Cohort B Pembrolizumab 400 mg IV
CellulitisInfections and infestations0/330/340/343/301/101
PneumoniaInfections and infestations0/330/340/340/304/101
AnaemiaBlood and lymphatic system disorders0/331/340/341/302/101
Adrenal insufficiencyEndocrine disorders0/330/340/341/300/101
Intestinal obstructionGastrointestinal disorders1/330/340/341/300/101
Hepatitis acuteHepatobiliary disorders0/330/340/341/300/101
InfectionInfections and infestations0/330/340/341/300/101
Tumour compressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/330/340/341/300/101
SeizureNervous system disorders0/330/340/341/300/101
Pleural disorderRespiratory, thoracic and mediastinal disorders0/330/340/341/300/101
Most frequent other events
Showing 10 of 52
Most frequent other events
EventCohort A Pembrolizumab 130 mg/mL SCCohort A Pembrolizumab 165 mg/mL SCCohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3)Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35)Cohort B Pembrolizumab 400 mg IV
ArthralgiaMusculoskeletal and connective tissue disorders3/332/340/347/3032/101
FatigueGeneral disorders0/331/340/347/3029/101
Alanine aminotransferase increasedInvestigations0/330/341/348/3014/101
VitiligoSkin and subcutaneous tissue disorders0/330/340/348/3025/101
RashSkin and subcutaneous tissue disorders2/330/341/345/3022/101
NauseaGastrointestinal disorders1/332/340/346/3017/101
PruritusSkin and subcutaneous tissue disorders1/331/341/346/3020/101
DiarrhoeaGastrointestinal disorders2/331/340/345/3020/101
AnaemiaBlood and lymphatic system disorders0/331/340/340/3016/101
Weight decreasedInvestigations2/330/340/342/3014/101

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort A Pembrolizumab Treatment Sequence 1Cohort A Pembrolizumab Treatment Sequence 2Cohort A Pembrolizumab Treatment Sequence 3Cohort A Pembrolizumab Treatment Sequence 4Cohort A Pembrolizumab Treatment Sequence 5Cohort A Pembrolizumab Treatment Sequence 6Cohort B Pembrolizumab 400 mg IVTotal
Mean60.9 ± 14.954.0 ± 20.158.2 ± 12.449.8 ± 16.759.8 ± 18.063.0 ± 22.562.1 ± 13.960.9 ± 14.9
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A Pembrolizumab Treatment Sequence 1Cohort A Pembrolizumab Treatment Sequence 2Cohort A Pembrolizumab Treatment Sequence 3Cohort A Pembrolizumab Treatment Sequence 4Cohort A Pembrolizumab Treatment Sequence 5Cohort A Pembrolizumab Treatment Sequence 6Cohort B Pembrolizumab 400 mg IVTotal
Female1113123645
Male6553456593
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A Pembrolizumab Treatment Sequence 1Cohort A Pembrolizumab Treatment Sequence 2Cohort A Pembrolizumab Treatment Sequence 3Cohort A Pembrolizumab Treatment Sequence 4Cohort A Pembrolizumab Treatment Sequence 5Cohort A Pembrolizumab Treatment Sequence 6Cohort B Pembrolizumab 400 mg IVTotal
Hispanic or Latino00000000
Not Hispanic or Latino54643593120
Unknown or Not Reported220222818
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A Pembrolizumab Treatment Sequence 1Cohort A Pembrolizumab Treatment Sequence 2Cohort A Pembrolizumab Treatment Sequence 3Cohort A Pembrolizumab Treatment Sequence 4Cohort A Pembrolizumab Treatment Sequence 5Cohort A Pembrolizumab Treatment Sequence 6Cohort B Pembrolizumab 400 mg IVTotal
American Indian or Alaska Native00000000
Asian00000011
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000088
White76665787124
More than one race00000044
Unknown or Not Reported00000011
08

Study locations

15 sites
  • Orange Health Services ( Site 0004)
    Orange, New South Wales 2800, Australia
  • Calvary Mater Newcastle ( Site 0006)
    Waratah, New South Wales 2298, Australia
  • Cairns and Hinterland Hospital and Health Service ( Site 0001)
    Cairns, Queensland 4870, Australia
  • Royal Adelaide Hospital ( Site 0002)
    Adelaide, South Australia 5000, Australia
  • Ballarat Health Services ( Site 0003)
    Ballarat, 3350, Australia
  • MNCCI Port Macquarie Base Hospital ( Site 0005)
    Port Macquarie, 2444, Australia
  • MPOC ( Site 0027)
    Groenkloof Pretoria, Gauteng 0181, South Africa
  • WITS Clinical Research CMJAH Clinical Trial Site ( Site 0030)
    Johannesburg, Gauteng 2193, South Africa
  • The Medical Oncology Centre of Rosebank ( Site 0026)
    Johannesburg, Gauteng 2196, South Africa
  • Cape Town Oncology Trials Pty Ltd ( Site 0028)
    Kraaifontein, Western Cape 7570, South Africa
  • Sandton Oncology Medical Group PTY LTD ( Site 0029)
    Johannesburg, 2196, South Africa
  • Hospital Universitari Vall d Hebron ( Site 0062)
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial de Barcelona ( Site 0061)
    Barcelona, 08036, Spain
  • Onkologikoa - Instituto Oncologico de San Sebastian ( Site 0063)
    San Sebastian, 20014, Spain
  • Karolinska Universitetssjukhuset Solna ( Site 0040)
    Solna, 171 64, Sweden
09

References and documents

Publications

  • Cohen G, Rapoport B, Chan SW, Ruff P, Arance A, Mujika Eizmendi K, Houghton B, Brown MP, Zielinski RM, Munoz Couselo E, Lyle M, Anderson JR, Jain L, de Alwis D, Lala M, Akala O, Chartash E, Jacobs C. Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PLoS One. 2024 Nov 12;19(11):e0309778. doi: 10.1371/journal.pone.0309778. eCollection 2024. PubMed 39531423 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Dec 2023, 60 months.

Results were first posted in Feb 2025, 1 year 2 months after primary completion.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 60 months is above that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2018
First posted
Sep 11, 2018
StartActual
Nov 19, 2018
Primary completionActual
Dec 4, 2023
CompletionActual
Dec 4, 2023
Results first posted
Feb 10, 2025
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03665597
Responsible party
Sponsor
First posted
Sep 11, 2018
Start date
Nov 19, 2018
Primary completion
Dec 4, 2023
Completion
Dec 4, 2023
Results posted
Feb 10, 2025
Last update
Feb 10, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion